Loading data for ACTU — first visit, this takes a few seconds.

Alerta

Actuate Therapeutics Inc.... (ACTU)

NasdaqGM: ACTU · Precio en tiempo real · USD

1.05

+0.06 (6.06%)

Al cierre: Aug 18, 2026, 8:00 PM

6.06% (1D)

No hay datos disponibles

Precio de compra	n/a
Capitalización de mercado	25.21M
Ingresos (TTM)	n/a
Beneficio neto (TTM)	-21.54M
Beta	n/a
EPS (TTM)	-0.92
Ratio PER (TTM)	n/a
Adelante PE	-1.45
P/B (TTM)	3.08
P/S (TTM)	n/a
Earnings Date	Nov 12, 2026

Precio de venta	n/a
Volumen	325,173
Volumen medio (20D)	266,350
Abierto	0.99
Anterior Cerrar	0.99
Rango del día	0.99 - 1.14
Rango de 52 semanas	0.90 - 9.22
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de ACTU

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Aug 13, 2024

Empleados 12

Bolsa de Valores NasdaqGM

Símbolo bursátil ACTU

Sitio web https://actuatetherapeutics.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Actuate Therapeutics Common stock fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -22.23M, una disminución de -18.54%.

Estados financieros

Sorpresa de resultados

Actuate Therapeutics Common stock ha publicado sus resultados trimestrales en Aug 14, 2026:

Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.

EPS de -0.2 falla las estimaciones por 0.00, con 33.33% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Actuate Therapeutics Inc. Common stock publique sus resultados el Nov 12, 2026, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

6 meses hace · Simply Wall St.

Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap dropped US$13m last week; Private equity firms bore the brunt

Key Insights The considerable ownership by private equity firms in Actuate Therapeutics indicates that they...

7 meses hace · MT Newswires

Actuate Therapeutics Plans to Advance Elraglusib in Ewing Sarcoma After Phase 1 Data

Actuate Therapeutics (ACTU) said Tuesday it plans to advance elraglusib in Ewing sarcoma and potenti

7 meses hace · Zacks

Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock?

Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

8 meses hace · Zacks

How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06%

The average of price targets set by Wall Street analysts indicates a potential upside of 214.1% in Actuate Therapeutics, Inc. (ACTU). While the effectiveness of this highly sought-after metric is ques...

9 meses hace · Simply Wall St.

Here's Why We're Watching Actuate Therapeutics' (NASDAQ:ACTU) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Página 1 de 2